The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Spring 2025 RFA: Molecular MRI Biomarker Program, 2025Novel Molecular Magnetic Resonance Imaging to Visualize and Quantify Impaired Brain Mitochondrial Bioenergetics in Parkinson's Disease
Study Rationale: Parkinson's disease (PD) is a neurodegenerative disease that affects the quality of life of more than one million people in the United States alone. Abnormal brain energy metabolism...
-
Spring 2025 RFA Seed Amplification Assay Innovation Program, 2025Development of an Efficient Method to Capture Synuclein Seeds from Biological Samples for Detection Using SynSAA
Study Rationale: Synuclein seeds detected in cerebrospinal fluid are the earliest sign of Parkinson’s disease (PD) identified to date. CSF has a simpler composition than blood or saliva. To detect...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology, 2025Structural determination of PD-associated GCase variants in complex with LIMP-2
Study Rationale: In Parkinson’s disease (PD), some of the most common genetic risk factors are changes in the GBA1 gene, which provides instructions to make the enzyme β-glucocerebrosidase (GCase)...
-
2021 RFA: Improved Outcome Measures, 2025Volatile Biomarkers of Prodromal Parkinson’s Disease from Sebum
Study Rationale: Researchers in the UK discovered biochemical molecules that are specifically present in the sebum, the oily substance produced by the skin, of people with Parkinson’s disease (PD) and...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Late-preclinical Development of a Differentiated TRPML1 Agonist to Slow Progression of Parkinson’s Disease
Study Rationale: TPRML1 is protein found on lysosomes, which serve as the cell’s degradation and recycling center. Lysosomes stop working properly in Parkinson’s disease and accumulate garbage...
-
T2T Validation - Endolysosomal Targets, 2025Development of Translational Biomarkers for TRPML1 Target Engagement in Intact Whole Human Parkinson’s Disease Brains
Study Rationale: TRPML1 is a promising drug target that offers the potential to slow the course of Parkinson’s disease. This study utilizes Bexorg’s revolutionary postmortem human brain platform to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.